Tuberculosis research and innovation: Interpretation of the WHO Global Tuberculosis Report 2021

doi:10.19982/j.issn.1000-6621.20210685

Abstract

Abstract:

Tuberculosis research and innovation is one of the three pillars to achieve the targets of End TB Strategy set by World Health Organization (WHO). On October 14, 2021, WHO released the Global tuberculosis report 2021, updating the newest progress of global tuberculosis research and innovation. This paper reviews the key achievements in the areas of research and innovation for new diagnostic, new drugs and new vaccines introduced in the global report, and discuss with consideration of China’s situation in related areas. The aim of this paper is to facilitate the better understanding to global research feature and development trend, and to provide reference for further China original scientific research and innovation.

Key words: Tuberculosis, Research, Consensus development conference

CLC Number:

SHU Wei, SUN Yu-xian, ZHANG Li-jie, XIE Shi-heng, GAO Jing-tao, LIU Yu-hong. Tuberculosis research and innovation: Interpretation of the WHO Global Tuberculosis Report 2021[J]. Chinese Journal of Antituberculosis, 2022, 44(1): 45-48. doi: 10.19982/j.issn.1000-6621.20210685

References 10

[1]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[2]	World Health Organization. Global strategy for tuberculosis research and innovation (WHA73.3). Geneva: World Health Organization, 2020.
[3]	World Health Organization. Situational assessment checklist to guide implementation of the global strategy for tuberculosis research and innovation. Geneva: World Health Organization, 2021.
[4]	World Health Organization. Compendium of TB/COVID-19 studies. Geneva: World Health Organization, 2021.
[5]	Treatment Action Group, Stop TB Partnership. Tuberculosis research funding trends 2005—2019. New York: Treatment Action Group, 2020.
[6]	Conradie F, Diacon AH, Ngubane N, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med, 2020, 382(10):893-902. doi: 10.1056/NEJMoa1901814. doi: 10.1056/NEJMoa1901814 URL
[7]	Dorman SE, Nahid P, Kurbatova EV, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med, 2021, 384(18):1705-1718. doi: 10.1056/NEJMoa2033400. doi: 10.1056/NEJMoa2033400 URL
[8]	Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2021, 27(4):597-602. doi: 10.1016/j.cmi.2020.06.004. doi: 10.1016/j.cmi.2020.06.004 URL
[9]	Gao JT, Du J, Wu GH, et al. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety. Infect Dis Poverty, 2021, 10(1):32. doi: 10.1186/s40249-021-00819-2. doi: 10.1186/s40249-021-00819-2 URL
[10]	Gebreselassie N, Hutubessy R, Vekemans J, et al. The case for assessing the full value of new tuberculosis vaccines. Eur Respir J, 2020, 55(3):1902414. doi: 10.1183/13993003.02414-2019. doi: 10.1183/13993003.02414-2019

[1]	CHEN Zhi, LIANG Jian-qin. Expert consensus on nutritional assessment and nutritional support treatment for patients with severe tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 421-432.
[2]	LIU Er-yong, CHEN Ming-ting, ZHOU Lin, MENG Qing-lin, WANG Jing. Novel patient-oriented care to advance tuberculosis control program [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 433-437.
[3]	HE Yi-jun, CAO Xue-fang, GAO Lei. Interpretation of the Procedure of tuberculin skin test-interferon-gamma release assay two-step testing [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 438-441.
[4]	WU Ming-qi, YAN Shi-chun, LIU Yu-qin, GUO Xin, WANG Mei-jie, TIAN Jing, HOU Shao-ying. Plasma proteomics analysis of diabetic patients complicated with pulmonary tuberculosis by iTRAQ technology [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 442-449.
[5]	DAI Guang-ming, WANG fen, CAO Ting-ming, CHU Hong-qian, HUANG Hai-rong, SUN Zhao-gang. Study on efficiency of Mycobacterium tuberculosis detection by real-time quantitative PCR with different clinical sample types and the improvement by grinding specimen with glass beads [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 450-454.
[6]	DUAN Li-yao, LING Yan-bo, LIANG Yan, SHI Ying-chang, WANG Lan, ZHAO Guan-ren, LIU Jun, ZHENG Yue, WU Xue-qiong. Preliminary study on serum pharmacochemistry of Niubeixiaohe extract [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 455-459.
[7]	WANG Ming-zhe, LIU Nian-qiang, Kaideliyan Abuduwaili, WANG Xin-qi, HUANG Fei. The impact of active case-finding on tuberculosis epidemic in four prefectures of Southern Xinjiang [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 460-466.
[8]	JIN Xiao-wei, LI Ya-ru, DUAN Hai-xia, WEI Xiao-hui, PEI Yi-yi, LI Ying, JIN Hong-jian. Study on active screening of pulmonary tuberculosis among key population in key areas of Xinmi, He’nan [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 467-472.
[9]	HU Yuan-lian, DENG Ling, AI Ping, JIA Xue-jiao, CHEN Wei, ZHANG Dong-yan, XUE Xiao, WU Qian-yu, XIE Jun-qing. Survey on the community treatment and management of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 473-477.
[10]	GONG De-hua, TANG Yi, TAN Wen-qian, WANG Qiao-zhi. Spatial-temporal analysis of tuberculosis among students in Hu’nan Province, during 2011—2020 [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 478-483.
[11]	XIONG Zi, XIE Ci-fu, SONG Li-xin, WANG Xiao-jun, TIAN Bin, HUANG Zhu-lin, XU Zu-hui, ZHANG Xi-xing, BAI Li-qiong. Epidemiological characteristics of MTB/HIV double infection in Changsha from 2011 to 2020 [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 484-488.
[12]	LIU Yuan, JU Meng, ZUO Lei, ZHANG Yao-hui, HUANG Yi. Comparative study on results of T-cell spot test for tuberculosis infection of peripheral blood and pleural effusion in tuberculous pleurisy patients complicated with type 2 diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 489-493.
[13]	XU Jing, LUO Ping, HE Xiao-xin. Comparative analysis of epidemiological characteristics of pulmonary tuberculosis complicated with diabetes and simple pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 494-499.
[14]	FEI Wan-wan, LU Zhen-hui, HUANG Xing, LI Cui, ZHANG Hui-yong, JIANG Yu-wei. Research progress on the correlation of gut microbiota with and pulmonary tuberculosis based on the theory of exterior and interior of lung and large intestine [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 500-504.
[15]	WU Chao-ling, DENG Guo-fang, FU Liang, YUAN Xiao-liang. Research progress of exhaled volatile organic compounds on the diagnosis of pulmonary infectious diseases [J]. Chinese Journal of Antituberculosis, 2022, 44(5): 505-511.